Rogers Jason H, Yeo Khung Keong, Carroll John D, Cleveland Joseph, Reece T Brett, Gillinov A Marc, Rodriguez Leonardo, Whitlow Patrick, Woo Y Joseph, Herrmann Howard C, Young J Nilas
University of California, Davis Medical Center, Sacramento, California, USA.
J Card Surg. 2009 Nov-Dec;24(6):677-81. doi: 10.1111/j.1540-8191.2009.00901.x. Epub 2009 Jul 24.
Percutaneous approaches for treating mitral regurgitation are under investigation, including repair with the MitraClip percutaneous mitral repair system (Evalve, Inc., Menlo Park, CA, USA), which has undergone extensive preclinical and clinical evaluation in the EVEREST I and II trials. The procedure involves the transcatheter placement of one or two MitraClip devices under echocardiographic and fluoroscopic guidance to restore leaflet coaptation. A desirable feature of any percutaneous mitral valve (MV) repair system is that the device should not impede subsequent surgical repair if needed. To date, the majority of reported MV surgeries after MitraClip device implantation have occurred earlier, within one year of treatment. We herein describe four previously unreported cases of successful surgical MV repair up to five years after MitraClip device implantation, demonstrating that late MV repair remains possible, including after implantation of two clips.
用于治疗二尖瓣反流的经皮治疗方法正在研究中,包括使用MitraClip经皮二尖瓣修复系统(Evalve公司,美国加利福尼亚州门洛帕克)进行修复,该系统已在EVEREST I和II试验中进行了广泛的临床前和临床评估。该手术包括在超声心动图和荧光透视引导下经导管放置一个或两个MitraClip装置,以恢复瓣叶对合。任何经皮二尖瓣(MV)修复系统的一个理想特性是,如果需要,该装置不应妨碍后续的手术修复。迄今为止,大多数报道的在植入MitraClip装置后进行的MV手术都发生在治疗后的一年内。我们在此描述了四例先前未报道的在植入MitraClip装置后长达五年成功进行手术MV修复的病例,表明晚期MV修复仍然可行,包括植入两个夹子后。